RU2748949C2 - Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака - Google Patents

Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака Download PDF

Info

Publication number
RU2748949C2
RU2748949C2 RU2018127164A RU2018127164A RU2748949C2 RU 2748949 C2 RU2748949 C2 RU 2748949C2 RU 2018127164 A RU2018127164 A RU 2018127164A RU 2018127164 A RU2018127164 A RU 2018127164A RU 2748949 C2 RU2748949 C2 RU 2748949C2
Authority
RU
Russia
Prior art keywords
agonist
ser
val
antibody
thr
Prior art date
Application number
RU2018127164A
Other languages
English (en)
Russian (ru)
Other versions
RU2018127164A3 (https=
RU2018127164A (ru
Inventor
Хуа ЛУН
Арон Дэвид ТОЛЛ
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2018127164A3 publication Critical patent/RU2018127164A3/ru
Publication of RU2018127164A publication Critical patent/RU2018127164A/ru
Application granted granted Critical
Publication of RU2748949C2 publication Critical patent/RU2748949C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018127164A 2016-01-25 2017-01-17 Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака RU2748949C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662286616P 2016-01-25 2016-01-25
US62/286,616 2016-01-25
PCT/IB2017/050244 WO2017130076A1 (en) 2016-01-25 2017-01-17 Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer

Publications (3)

Publication Number Publication Date
RU2018127164A3 RU2018127164A3 (https=) 2020-02-28
RU2018127164A RU2018127164A (ru) 2020-02-28
RU2748949C2 true RU2748949C2 (ru) 2021-06-02

Family

ID=57956335

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127164A RU2748949C2 (ru) 2016-01-25 2017-01-17 Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака

Country Status (12)

Country Link
US (1) US20190031765A1 (https=)
EP (1) EP3408294A1 (https=)
JP (1) JP6783312B2 (https=)
KR (2) KR20180103150A (https=)
CN (1) CN108473587A (https=)
AU (2) AU2017211540B2 (https=)
BR (1) BR112018014016A2 (https=)
CA (1) CA2955184A1 (https=)
HK (1) HK1259253A1 (https=)
MX (1) MX2018008995A (https=)
RU (1) RU2748949C2 (https=)
WO (1) WO2017130076A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
CN110357961B (zh) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 抗人4-1bb单克隆抗体及其制备方法和用途
US12054554B2 (en) 2018-04-10 2024-08-06 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020240360A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
JP2022550297A (ja) 2019-09-25 2022-12-01 ファイザー・インク Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
US20230112470A1 (en) 2020-01-29 2023-04-13 Board Of Regents, The University Of Texas System Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
US20240182593A1 (en) * 2021-05-27 2024-06-06 Yuhan Corporation Ox40 agonist and use thereof
CN118684772A (zh) * 2021-09-09 2024-09-24 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
JP2024536133A (ja) 2021-09-29 2024-10-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗ｈｓｐ７０抗体およびその治療的使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010129045A (ru) * 2007-12-14 2012-01-20 Бристоль-Мейерз Сквибб Компани (US) Связывающие молекулы к рецептору ох40 человека
US20120237498A1 (en) * 2010-09-09 2012-09-20 Pfizer Inc 4-1bb binding molecules
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US20060153808A1 (en) 2004-11-17 2006-07-13 Board Of Regents, The Universtiy Of Texas System Cancer immunotherapy incorporating p53
CA2610661A1 (en) 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
CN103619571B (zh) 2011-06-30 2016-08-17 米其林研究和技术股份有限公司 用于将胎面环安装到轮胎胎体上的方法和设备
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
PH12017501857B1 (en) * 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010129045A (ru) * 2007-12-14 2012-01-20 Бристоль-Мейерз Сквибб Компани (US) Связывающие молекулы к рецептору ох40 человека
US20120237498A1 (en) * 2010-09-09 2012-09-20 Pfizer Inc 4-1bb binding molecules
WO2015179236A1 (en) * 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADLER AJ. "Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation", OncoImmunology, Vol. 2(1), p. e22837, 2013. *
ADLER AJ. "Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation", OncoImmunology, Vol. 2(1), p. e22837, 2013. QUI HZ et al. "CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells to Program Cytotoxic Th1 Differentiation", J Immunol, 2011, Vol. 187(7), pp. 3555-3564. GRAY JC. "Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies", Eur. J. Immunol, 2008, Vol. 38, pp. 2499-2511. LEE SJ et al. "4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function", J Immunol, 2004, Vol. 173, pp. 3002-3012. *
GRAY JC. "Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies", Eur. J. Immunol, 2008, Vol. 38, pp. 2499-2511. *
LEE SJ et al. "4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function", J Immunol, 2004, Vol. 173, pp. 3002-3012. *
QUI HZ et al. "CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells to Program Cytotoxic Th1 Differentiation", J Immunol, 2011, Vol. 187(7), pp. 3555-3564. *

Also Published As

Publication number Publication date
MX2018008995A (es) 2019-01-10
CA2955184A1 (en) 2017-07-25
EP3408294A1 (en) 2018-12-05
AU2020210145A1 (en) 2020-08-13
HK1259253A1 (zh) 2019-11-29
BR112018014016A2 (pt) 2019-02-05
CN108473587A (zh) 2018-08-31
US20190031765A1 (en) 2019-01-31
AU2017211540A1 (en) 2018-07-19
JP2019506403A (ja) 2019-03-07
RU2018127164A3 (https=) 2020-02-28
JP6783312B2 (ja) 2020-11-11
WO2017130076A1 (en) 2017-08-03
AU2017211540B2 (en) 2020-04-30
RU2018127164A (ru) 2020-02-28
KR20180103150A (ko) 2018-09-18
KR20210013777A (ko) 2021-02-05

Similar Documents

Publication Publication Date Title
RU2748949C2 (ru) Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака
US12534530B2 (en) Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US10899840B2 (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
RU2705795C2 (ru) Лечение рака комбинацией антагониста pd-1 и динациклиба
US10023649B2 (en) Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
JP7470105B2 (ja) 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer